Current mitigation strategies include patient stratification according to disease type and tumor burden, and close monitoring of patients so that high grade CRS/neurotoxicity can be avoided (typically with the combined use of the IL6R inhibitor tocilizumab and steroids)38,39. The gene discussed is IL6R; the disease is congenital rubella syndrome.